Truist Securities Maintains Buy on Genmab, Raises Price Target to $45
Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $45.
Stocks · News reference
Genmab Reports Q3 DARZALEX Net Sales Of $4.239B
Worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on Genmab, Raises Price Target to $58
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $50
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $50.